Last updated: February 27, 2026
What is NDC 60687-0930?
NDC 60687-0930 is a biologic drug. Details regarding the specific product, including manufacturer, active ingredient, and approved indications, are not publicly disclosed in the available data. The absence of detailed product information limits precise market and pricing forecasts.
What is the current market landscape for biologics similar to NDC 60687-0930?
Biologics are a dominant segment in the pharmaceutical industry, with global sales reaching approximately $250 billion in 2022[1]. The market growth rate remains around 10% annually, driven by aging populations, expanding indications, and increasing biologic approvals.
Key players in biologics include:
- Roche
- Amgen
- AbbVie
- Pfizer
- Eli Lilly
Products targeting autoimmune diseases, cancers, and rare conditions constitute the majority of their portfolios.
Market segments involved:
- Oncology (approximately 40% of biologic sales)
- Autoimmune disorders (around 30%)
- Viral infections (around 15%)
- Others (15%)
How does competitive positioning influence potential market share?
Development pipelines include multiple biosimilars and innovator products targeting the same indications. Biosimilars threaten price erosion and market share, especially in regions with cost-focused reimbursement systems.
Key factors influencing market share include:
- Patent exclusivity duration
- Regulatory approval timelines
- Reimbursement policies
- Clinical efficacy and safety profile
What are the pricing trends for similar biologic drugs?
Average wholesale prices (AWPs) for biologics range from $2,000 to $8,000 per dose, depending on the indication and complexity. For instance:
| Product |
Typical Price per Dose |
Indication |
Date of Data (2022) |
| Adalimumab (Humira) |
$2,500 – $3,000 |
Rheumatoid arthritis |
2022 |
| Rituximab (Rituxan) |
$3,500 – $4,500 |
Non-Hodgkin lymphoma |
2022 |
| Trastuzumab (Herceptin) |
$4,000 – $6,000 |
Breast cancer |
2022 |
Price reductions are occurring as biosimilars enter the market, with discounts of 15-30% observed in mature markets.
What are the projections for the drug’s future market value?
Considering the trend of increasing biologic adoption and pending biosimilar competition, the following projection can be forecasted:
-
Short-term (1-3 years): Market share stabilizes with modest price declines of 10-15%. The drug maintains a key position if it receives regulatory approval for multiple indications and demonstrates strong clinical data.
-
Medium-term (4-7 years): Biosimilar entry potentially reduces prices by 20-30%. If the patent remains active, the product can sustain revenue through exclusive rights for certain indications.
-
Long-term (8+ years): Market consolidation and biosimilar proliferation could reduce prices by up to 50% across regions. The combined effect can lead to a 30-50% decline in revenue potential compared to initial launch phase.
Assumptions are based on current biosimilar market dynamics and regulatory trends (e.g., FDA and EMA approvals, patent litigation).
What is the regulatory landscape influencing pricing and market entry?
Regulatory pathways mainly include:
- BLA (Biologics License Application) approval
- Patent litigation disputes
- Biosimilar pathway approval
Recent policies aim to streamline biosimilar approval, potentially increasing market competition. Countries such as the U.S. and EU are optimizing frameworks for biosimilar entry, which may accelerate price erosion.
Key factors impacting price projection accuracy
- Timing of regulatory approvals
- Patent expiry dates
- Market uptake speed
- Competitive biosimilar pipeline development
- Reimbursement policy changes
Summary
| Factor |
Impact on Price and Market Share |
| Patent exclusivity |
Maintains higher prices; expiring patents lead to biosimilar entry |
| Biosimilar competition |
Drives prices down by 15-50% over 5-7 years |
| Clinical efficacy/safety profile |
Influences adoption and patient preference |
| Reimbursement policies |
Affects accessibility and pricing structures |
Key Takeaways
- Limited publicly available data on NDC 60687-0930 restricts precise forecasts.
- The biologic market is highly competitive, with significant biosimilar threat.
- Prices for comparable biologics range from $2,000 to over $6,000 per dose.
- Entry of biosimilars is expected to lower prices globally over the next 5-7 years.
- Market exclusivity, regulatory pathways, and clinical performance influence revenue trajectory.
FAQs
- How soon can biosimilars for NDC 60687-0930 enter the market?
- What are the primary regulatory challenges for biologic price stabilization?
- How does patent expiration impact global pricing strategies?
- Which regions are most aggressive in biosimilar adoption?
- What factors could extend exclusivity beyond patent protections?
References
[1] IQVIA Institute. (2022). The Global Use of Medicines in 2022.
